Integra Therapeutics is a spin-off company from Universitat Pompeu Fabra (UPF). The company is focused on the development of a gene editing platform based on the combination of engineered CRISPR systems with viral integrases and transposases which allow for stable and precise integration of full-length genes of any size, for treating genetic and oncologic diseases, both in vivo and ex vivo.
- CEO & Cofounder: Avencia Sánchez-Mejías
- CSO & Cofounder: Marc Güell Cargol
- Location: Barcelona
- Website: integra-tx.com